Bioseal Dural Sealing Study BIOS-14-001

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-14

Study Completion Date

2019-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Prospective, Randomized, Controlled, Single Blinded, Study to Evaluate the Safety and Effectiveness of Bioseal as an Adjunct to Sutured Dural Repair

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase IV Bioseal Study in Brain Tumor Surgery

NCT02034799

Hemostasis Meningioma Surgery

COMPLETED PHASE4

Tumor Electric Fields Treatment System for Glioblastoma

NCT04417933

Glioblastoma

UNKNOWN EARLY_PHASE1

Diagnostic Efficiency of Artificial Intelligence for Surgical Neuropathology

NCT04671368

Central Nervous System Neoplasms

UNKNOWN NA

Cerebral, Meningeal Biopsy by Flexible Endoscopy in Patients Without Neurological Diagnosis

NCT01073280

Neurological Disease

UNKNOWN

Analysis of Circulating DNA in Blood Samples of Glioma-affected Patients

NCT05964153

Glioma Circulating Tumor Cell

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, single blinded, multi-center controlled study evaluating the effectiveness of Bioseal as an adjunct to sutured dural closure compared to control to obtain an intra-operative watertight dural closure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Tumors Malignant Tumors Vascular Malformation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

suture (control)

Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.

Group Type NO_INTERVENTION

No interventions assigned to this group

Bioseal

Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.

Group Type EXPERIMENTAL

Bioseal

Intervention Type BIOLOGICAL

Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bioseal

Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Preoperative

1. Patient undergoing elective craniotomy/craniectomy for pathological processes (such as benign and malignant tumors, vascular malformation) in the posterior fossa or in the supratentorial region.
2. Age ≥ 18 years.
3. Patients who are able and willing to comply with the procedures required by the protocol.
4. Signed and dated written informed consent from the subject or from his/her legal representative prior to any study-specific procedures.
* Intraoperative

1. Patient undergoing elective craniotomy/craniectomy for pathological processes (such as benign and malignant tumors, vascular malformation) in the posterior fossa or in the supratentorial region and who are demonstrated to have persistent CSF leakage following suture closure of the dural incision. CSF leakage will be evaluated during a period of Valsalva of 10-20 cm of H20 for 5-10 seconds. If a spontaneous leak is apparent immediately after dural closure, no Valsalva will be performed.
2. Surgical wound classification Class I. Penetration of mastoid air cells during partial mastoidectomy is permitted.
3. The cuff of native dura along the craniotomy edge is ≥10 mm wide, to facilitate suturing and to allow for sufficient surface area for adherence of the investigational product.

Exclusion Criteria

* Preoperative

1. Subjects with a dura lesion from a recent surgery that still has the potential for CSF leakage.
2. The previous craniotomy/ craniectomy within 6 months or radiation therapy within 2 years before this surgery.
3. Chemotherapy or radiation therapy scheduled within 7 days following surgery.
4. Subjects with severely altered renal (serum creatinine \>2 mg/dL) and/or hepatic function \[ALT, AST \> 5 x upper limit of norm (ULN)\].
5. Severe Anemia (Hemoglobin \<60 g/L) or Hypoproteinemia (Total protein \<60 g/L or 6g% ) .
6. Non-compliant or insufficient treatment of diabetes mellitus \[glycosylated hemoglobin (HbA1c) \> 7.5%\].
7. Conditions compromising the immune system; existence of autoimmune disease.
8. Evidence of a potential infection: fever \>38℃, WBC \<3500/uL or \>13000/uL, positive urine culture, positive blood culture, positive chest X-ray, evidence of infection along the planned surgical path.
9. Known hypersensitivity to the porcine fibrin sealant product.
10. Female subjects of childbearing potential with a positive urine or serum pregnancy test within 7 days prior to surgery.
11. Female subjects who are breastfeeding or intend to become pregnant during the clinical study period.
12. Participation in another clinical trial with exposure to another investigational drug or device within 30 days prior to enrolment.
* Intraoperative

1. Native dura cuff during craniotomy/craniectomy that cannot be completely repaired.
2. Use of implants made of synthetic materials coming into direct contact with dura (e.g., PTFE patches, shunts, ventricular and subdural drains).
3. Occlusive hydrocephalus caused by posterior fossa pathology or partial blockage of CSF pathways during surgical procedure.
4. Existing CSF drains on the surgical path.
5. Use of other fibrin sealants for hemostasis.
6. Placement of Gliadel Wafers or similar products.
7. Persistently increased brain surface tension that may lead to an incomplete repair requiring.
8. Intersecting durotomy scars in the surgical path from a previous operation that cannot be completely removed by the planned dura resection.
9. Two or more separate dura defects during surgery.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No